|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ______________ to _______________
Commission File Number
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of | (I.R.S. Employer |
incorporation or organization) | Identification No.) |
(Address of principal executive offices)
(Zip Code)
(
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period than the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer ☐ |
|
|
Smaller reporting company | |
|
|
| Emerging growth company |
If an emerging growth company, indicate by check mark whether the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of August 11, 2022, the issuer had
TABLE OF CONTENTS
2
PART I-FINANCIAL INFORMATION
ITEM 1. CONDENSED FINANCIAL STATEMENTS
IDEAL POWER INC.
Balance Sheets
(unaudited)
June 30, | December 31, | |||||
| 2022 |
| 2021 | |||
ASSETS |
|
|
|
| ||
Current assets: |
|
|
|
| ||
Cash and cash equivalents | $ | | $ | | ||
Accounts receivable, net | | | ||||
Prepayments and other current assets |
| |
| | ||
Total current assets |
| |
| | ||
|
| |||||
Property and equipment, net |
| |
| | ||
Intangible assets, net |
| |
| | ||
Right of use asset |
| |
| | ||
Other assets |
| |
| | ||
Total assets | $ | | $ | | ||
| ||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
| ||
Current liabilities: |
|
|
|
| ||
Accounts payable | $ | | $ | | ||
Accrued expenses |
| |
| | ||
Current portion of lease liability |
| |
| | ||
Total current liabilities |
| |
| | ||
Long-term lease liability |
| |
| | ||
Other long-term liabilities |
| |
| | ||
Total liabilities |
| |
| | ||
| ||||||
Commitments and contingencies (Note 6) |
|
|
|
| ||
| ||||||
Stockholders’ equity: |
|
|
|
| ||
Common stock, $ |
| |
| | ||
Additional paid-in capital |
| |
| | ||
Treasury stock, at cost, |
| ( |
| ( | ||
Accumulated deficit |
| ( |
| ( | ||
Total stockholders’ equity |
| |
| | ||
Total liabilities and stockholders’ equity | $ | | $ | | ||
The accompanying notes are an integral part of these condensed financial statements.
3
IDEAL POWER INC.
Statements of Operations
(unaudited)
Three Months Ended | Six Months Ended | |||||||||||
June 30, | June 30, | |||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | |||||
Grant revenue | $ | | $ | | $ | | $ | | ||||
Cost of grant revenue |
| |
| |
| |
| | ||||
Gross profit |
| |
| |
| |
| | ||||
|
|
|
| |||||||||
Operating expenses: |
|
|
|
|
|
|
|
| ||||
Research and development |
| |
| |
| |
|
| | |||
General and administrative |
| |
| |
| |
|
| | |||
Sales and marketing | | | |
| | |||||||
Total operating expenses |
| |
| |
| |
|
| | |||
|
|
|
| |||||||||
Loss from operations |
| ( |
| ( |
| ( |
| ( | ||||
Other income: | ||||||||||||
Interest income (expense), net |
| |
| ( |
| |
| ( | ||||
Gain on forgiveness of long-term debt | — | | — | | ||||||||
Total other income | | | | | ||||||||
Net loss | $ | ( | $ | ( | $ | ( | $ | ( | ||||
|
|
| ||||||||||
Net loss per share – basic and diluted | ( | ( | ( | ( | ||||||||
|
|
| ||||||||||
Weighted average number of shares outstanding – basic and diluted |
| |
| |
| |
| | ||||
The accompanying notes are an integral part of these condensed financial statements.
4
IDEAL POWER INC.
Statements of Cash Flows
(unaudited)
Six Months Ended | ||||||
June 30, | ||||||
| 2022 |
| 2021 | |||
Cash flows from operating activities: |
|
| ||||
Net loss | $ | ( | $ | ( | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
| ||
Depreciation and amortization |
| |
| | ||
Write-off of capitalized patents |
| |
| | ||
Stock-based compensation |
| |
| | ||
Stock issued for services | | | ||||
Gain on forgiveness of long-term debt | | ( | ||||
Decrease (increase) in operating assets: |
|
|
|
| ||
Accounts receivable | | | ||||
Prepaid expenses and other assets |
| ( |
| ( | ||
Increase (decrease) in operating liabilities: |
|
|
|
| ||
Accounts payable |
| ( |
| | ||
Accrued expenses and other liabilities |
| |
| | ||
Net cash used in operating activities |
| ( |
| ( | ||
|
| |||||
Cash flows from investing activities: |
|
|
|
| ||
Purchase of property and equipment |
| ( |
| ( | ||
Acquisition of intangible assets |
| ( |
| ( | ||
Net cash used in investing activities |
| ( |
| ( | ||
| ||||||
Cash flows from financing activities: |
| |||||
Net proceeds from issuance of common stock | | | ||||
Exercise of options and warrants | | | ||||
Net cash provided by financing activities | | | ||||
|
| |||||
Net increase (decrease) in cash and cash equivalents |
| ( |
| | ||
Cash and cash equivalents at beginning of period |
| |
| | ||
Cash and cash equivalents at end of period | $ | | $ | | ||
The accompanying notes are an integral part of these condensed financial statements.
5
IDEAL POWER INC.
Statements of Stockholders’ Equity
For the Three-Month Periods during the Six Months Ended June 30, 2022 and 2021
(unaudited)
Additional | Total | ||||||||||||||||||
Common Stock | Paid-In | Treasury Stock | Accumulated | Stockholders’ | |||||||||||||||
| Shares |
| Amount |
| Capital |
| Shares |
| Amount |
| Deficit |
| Equity | ||||||
Balances at December 31, 2020 | | $ | | $ | | | $ | ( | $ | ( | $ | | |||||||
Issuance of shares of common stock in public offering | | | | — | — | — | | ||||||||||||
Exercise of options and warrants | | | | — | — | — | | ||||||||||||
Stock issued for services | | | | — | — | — | | ||||||||||||
Stock-based compensation |
| — | — |
| |
| — | — | — | | |||||||||
Net loss for the three months ended March 31, 2021 | — | — | — | — | — | ( | ( | ||||||||||||
Balances at March 31, 2021 | | | | | ( | ( | | ||||||||||||
Stock-based compensation | — | — | | — | — | — | | ||||||||||||
Net loss for the three months ended June 30, 2021 | — | — | — | — | — | ( | ( | ||||||||||||
Balances at June 30, 2021 |
| | $ | |
| $ | |
| | $ | ( | $ | ( | $ | | ||||
Balances at December 31, 2021 | | $ | | $ | | | $ | ( | $ | ( | $ | | |||||||
Exercise of options | | | ( | — | — | — | — | ||||||||||||
Stock issued for services | | | | — | — | — | | ||||||||||||
Stock-based compensation | — | — | | — | — | — | | ||||||||||||
Net loss for the three months ended March 31, 2022 | — | — | — | — | — | ( | ( | ||||||||||||
Balances at March 31, 2022 | | | | | ( | ( | | ||||||||||||
Stock-based compensation | — | — | | — | — | — | | ||||||||||||
Net loss for the three months ended June 30, 2022 | — | — | — | — | — | ( | ( | ||||||||||||
Balances at June 30, 2022 | | $ | | $ | | | $ | ( | $ | ( | $ | | |||||||
The accompanying notes are an integral part of these condensed financial statements.
6
Ideal Power Inc.
Notes to Financial Statements
(unaudited)
Note 1 – Organization and Description of Business
Ideal Power Inc. (the “Company”) was incorporated in Texas on May 17, 2007 under the name Ideal Power Converters, Inc. The Company changed its name to Ideal Power Inc. on July 8, 2013 and re-incorporated in Delaware on July 15, 2013. With headquarters in Austin, Texas, the Company is focused on the further development and commercialization of its Bidirectional bipolar junction TRANsistor (B-TRAN™) solid state switch technology.
Since its inception, the Company has financed its research and development efforts and operations primarily through the sale of common stock and warrants. The Company’s continued operations are dependent upon, among other things, its ability to obtain adequate sources of funding through future revenues, securities offerings, debt financing, co-development agreements, government grants, sale or licensing of developed intellectual property or other alternatives.
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The balance sheet at December 31, 2021 has been derived from the Company’s audited financial statements included in its Annual Report on Form 10-K filed with the SEC on March 25, 2022.
In the opinion of management, these financial statements reflect all normal recurring, and other adjustments, necessary for a fair presentation. These financial statements should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.
Net Loss Per Share
In accordance with Accounting Standards Codification 260, shares issuable for little or no cash consideration are considered outstanding common shares and included in the computation of basic net loss per share. As such, for the three and six months ended June 30, 2022 and 2021, the Company included pre-funded warrants to purchase
In periods with a net loss, no common share equivalents are included in the computation of diluted net loss per share because their effect would be anti-dilutive. At June 30, 2022, potentially dilutive shares outstanding amounted to
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting standard, if adopted, would have a material impact on the Company’s financial statements.
7
Note 3 – Intangible Assets
Intangible assets, net consisted of the following:
June 30, | December 31, | |||||
| 2022 |
| 2021 | |||
(unaudited) | ||||||
Patents | $ | | $ | | ||
Other intangible assets |
| |
| | ||
| |
| | |||
Accumulated amortization – patents | ( | ( | ||||
Accumulated amortization – other intangible assets |
| ( |
| ( | ||
$ | | $ | | |||
Amortization expense amounted to $
At June 30, 2022 and December 31, 2021, the Company had capitalized $
Note 4 – Loans
In May 2020, the Company entered into a Loan Agreement and Promissory Note (collectively the PPP Loan) with BBVA USA pursuant to the Paycheck Protection Program (the PPP) under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) administered by the U.S. Small Business Administration (SBA). The Company received total proceeds of $
Note 5 – Lease
The Company previously leased
In March 2021, the Company entered into a lease agreement for
For purposes of calculating the right of use asset and lease liability included in the Company’s financial statements, the Company estimated its incremental borrowing rate at
8
Future minimum payments under the lease are as follows:
For the Year Ended December 31, |
| ||
2022 (remaining) | $ | | |
2023 |
| | |
2024 |
| | |
2025 |
| | |
2026 |
| | |
Total lease payments | | ||
Less: imputed interest |
| ( | |
Total lease liability | $ | |
At June 30, 2022, the remaining lease term was
For the three months ended June 30, 2022 and 2021, operating cash flows for lease payments totaled $
Note 6 – Commitments and Contingencies
License Agreement
In 2015, the Company entered into licensing agreements which expire in February 2033. Pursuant to these agreements, the Company has an exclusive royalty-free license associated with semiconductor power switches which enhances its intellectual property portfolio. The agreements include both fixed payments, all of which were paid prior to 2017, and ongoing variable payments. The variable payments are a function of the number of associated patent filings pending and patents issued under the agreements. The Company will pay $
At June 30, 2022 and December 31, 2021, the other long-term liability for the estimated present value of future payments under the licensing agreements was $
Legal Proceedings
The Company may be subject to litigation from time to time in the ordinary course of business. The Company is not currently party to any legal proceedings.
Indemnification Obligations
The employment agreements of Company executives include an indemnification provision whereby the Company shall indemnify and defend, at the Company’s expense, its executives so long as an executive’s actions were taken in good faith and in furtherance of Company’s business and within the scope of executive’s duties and authority.
9
COVID-19 Pandemic
As of the date of these financial statements, the COVID-19 pandemic continues to spread throughout the United States and the rest of the world. The ultimate extent of the impact of COVID-19 on the financial performance of the Company will depend on future developments, including, among other things, the duration and spread of COVID-19 and its related variants, the timing, scope and efficacy of vaccination efforts, additional governmental restrictions in response to the COVID-19 pandemic and the overall economy, all of which are highly uncertain and cannot be predicted. If the COVID-19 pandemic contributes to additional significant volatility in the global financial markets in the future, the Company’s ability to raise additional capital, if necessary, on acceptable terms or at all, may be impacted, though such risk has not materialized to date. If the financial markets and/or the overall economy are negatively impacted for an extended period, the Company’s operating results may be materially and adversely affected.
Note 7 — Common Stock
Public Offering
In February 2021, the Company issued and sold
Stock Issuances
In January 2022, the Company issued
Note 8 — Equity Incentive Plan
In May 2013, the Company adopted the 2013 Equity Incentive Plan (as amended and restated, the “Plan”) and reserved shares of common stock for issuance under the Plan, which was last amended in June 2021. The Plan is administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). At June 30, 2022,
A summary of the Company’s stock option activity and related information is as follows:
Weighted | |||||||
Weighted | Average | ||||||
Average | Remaining | ||||||
Stock | Exercise | Life | |||||
| Options |
| Price |
| (in years) | ||
Outstanding at December 31, 2021 |
| | $ | |
| ||
Granted |
| | $ | |
|
| |
Exercised |
| ( | $ | |
| ||
Forfeited | ( | $ | | ||||
Outstanding at June 30, 2022 |
| | $ | |
| ||
Exercisable at June 30, 2022 |
| | $ | |
| ||
During the six months ended June 30, 2022, the Company granted
In January 2022, the Compensation Committee of the Board approved a modification of stock option grants to David Eisenhaure, the Company’s former Chairman of the Board, who passed away in October 2021. The modification extended the post-termination exercise period of his vested stock option grants from
10
At June 30, 2022 and December 31, 2021, there were
At June 30, 2022, there was $
Note 9 — Warrants
At June 30, 2022 and December 31, 2021, the Company had
At June 30, 2022, all warrants are exercisable, although the warrants held by certain of the Company’s warrant holders may be exercised only to the extent that the total number of shares of common stock then beneficially owned by such warrant holder does not exceed
11
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION CONTAINED IN THIS REPORT
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements include, but are not limited to, statements regarding our future financial performance, business condition and results of operations and pursuing additional government funding. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “would,” “should,” “could,” “may” or other similar expressions in this report. In particular, these include statements relating to future actions, prospective products, applications, customers, technologies, future performance or results of anticipated products, expenses, and financial results. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:
| ● | our history of losses; |
| ● | our ability to generate revenue; |
| ● | our limited operating history; |
| ● | the size and growth of markets for our technology; |
| ● | regulatory developments that may affect our business; |
| ● | our ability to successfully develop new technologies, particularly our bidirectional bipolar junction transistor, or B-TRAN™; |
| ● | our expectations regarding the timing of prototype and commercial fabrication of B-TRAN™ devices; |
| ● | our expectations regarding the performance of our B-TRAN™ and the consistency of that performance with both internal and third-party simulations; |
| ● | the expected performance of future products incorporating our B-TRAN™; |
| ● | the performance of third-party consultants and service providers whom we have and will continue to rely on to assist us in development of our B-TRAN™ and related drive circuitry; |
| ● | the rate and degree of market acceptance for our B-TRAN™; |
| ● | the time required for third parties to redesign, test and certify their products incorporating our B-TRAN™; |
| ● | our ability to successfully commercialize our B-TRAN™ technology; |
| ● | our ability to secure strategic partnerships with semiconductor fabricators and others related to our B-TRAN™ technology; |
| ● | our ability to obtain, maintain, defend and enforce intellectual property rights protecting our technology; |
| ● | the success of our efforts to manage cash spending, particularly prior to the commercialization of our B-TRAN™ technology; |
| ● | general economic conditions and events and the impact they may have on us and our potential partners and licensees; |
12
| ● | our ability to obtain adequate financing in the future, if and when we need it; |
| ● | the impact of the novel coronavirus (COVID-19) on our business, financial condition and results of operations; |
| ● | our success at managing the risks involved in the foregoing items; and |
| ● | other factors discussed in this report. |
The forward-looking statements are based upon management’s beliefs and assumptions and are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking statements included in this report. You should not place undue reliance on these forward-looking statements.
Unless otherwise stated or the context otherwise requires, the terms “Ideal Power,” “we,” “us,” “our” and the “Company” refer to Ideal Power Inc.
13
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited 2021 financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021. In addition to historical information, the discussion and analysis here and throughout this Form 10-Q contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021.
Overview
Ideal Power Inc. is located in Austin, Texas. The Company is solely focused on the further development and commercialization of its Bidirectional bipolar junction TRANsistor (B-TRAN™) solid state switch technology.
To date, operations have been funded primarily through the sale of common stock and warrants. Total revenue generated from inception to date as of June 30, 2022 amounted to $16.1 million with approximately $12.4 million of that revenue from discontinued operations and the remainder from grant revenue for bidirectional power switch development. Revenue was $50,978 and $175,986 in the three months and six months ended June 30, 2022, respectively, and $84,705 and $326,766 in the three and six months ended June 30, 2021, respectively. Revenue for the three and six months ended June 30, 2022 and 2021 related to government grants. We may pursue additional research and development grants, if and when available, to further develop and/or improve our technology.
COVID-19 Impact
As of the date of this report, the COVID-19 pandemic continues to spread throughout the United States and the rest of the world. The ultimate extent of the impact of COVID-19 on our financial performance will depend on future developments, including, among other things, the duration and spread of COVID-19 and its related variants, the timing, scope and efficacy of vaccination efforts, additional governmental restrictions in response to the COVID-19 pandemic, and the overall economy, all of which are highly uncertain and cannot be predicted. If the COVID-19 pandemic contributes to significant additional volatility in the global financial markets in the future, our ability to raise additional capital, if necessary, on acceptable terms or at all, may be impacted, though such risk has not materialized to date. If the financial markets and/or the overall economy are negatively impacted for an extended period, our operating results may be materially and adversely affected.
While the COVID-19 pandemic has caused some disruption to our business, it has not had a material adverse impact on our operations to date. However, the COVID-19 pandemic may disrupt our business in the future and cause electrical component shortages and unavailability, difficulties in securing fabrication capacity, delays in critical development and commercialization activities and/or result in potential incremental costs associated with mitigating the effects of the COVID-19 pandemic. There has been a significant disruption in the supply chain for semiconductors due both to the COVID-19 pandemic and increased demand for semiconductors. While this disruption has not materially impacted us to date, it may materially and adversely impact us in the future. The COVID-19 pandemic is ongoing, and its dynamic nature, including uncertainties relating to the ultimate spread of the virus and its related variants, the duration of the pandemic, the timing, scope and efficacy of vaccination efforts and additional actions that may be taken by governmental authorities in response to the pandemic, makes it difficult to forecast the effects on our business and results of operations for the remainder of 2022 and thereafter.
14
Results of Operations
Comparison of the three months ended June 30, 2022 to the three months ended June 30, 2021
Grant Revenues. Grant revenues for the three months ended June 30, 2022 and 2021 were $50,978 and $84,705, respectively. The grant revenues relate to a $1.2 million subcontract with Diversified Technologies, Inc. (“DTI”) to supply B-TRAN™ devices as part of a two-year contract awarded to DTI by the United States Naval Sea Systems Command (“NAVSEA”) for the development and demonstration of a B-TRAN™ enabled high efficiency direct current solid state circuit breaker (“SSCB”). In June 2022, NAVSEA approved a 6-month extension to the program and the program is currently expected to be completed by the end of the year. We expect the remaining grant revenue of $64,671 related to this subcontract to be recognized during the third and fourth quarters of this year. We also expect to pursue additional government funding that may result in additional grant revenues in the future.
We expect to introduce our initial product for commercial sale as early as late 2022.
Cost of Grant Revenues. Cost of grant revenues for the three months ended June 30, 2022 and 2021 was $50,978 and $84,705, respectively. The cost of grant revenues relates to the subcontract with DTI discussed above and are equal to the associated grant revenues resulting in no gross profit. We expect no gross profit under the subcontract with DTI or from other grants that we are pursuing or may pursue in the remainder of 2022.
Research and Development Expenses. Research and development expenses increased by $167,690, or 30%, to $728,383 in the three months ended June 30, 2022 from $560,693 in the three months ended June 30, 2021. The increase was due to higher semiconductor fabrication costs of $115,061, wafer and driver component costs of $95,212 and higher stock-based compensation expense of $70,689, partly offset by lower contract labor costs of $71,692 and other B-TRAN™ development spending of $41,580. In the three months ended June 30, 2021, our semiconductor fabrication costs were partially funded by government grants. In the three months ended June 30, 2022, almost all of our semiconductor fabrication costs were not funded by government grants. We expect higher research and development expenses in the remainder of 2022 as we continue to accelerate development of our B-TRAN™ technology and self-fund, at least in the short term, semiconductor fabrication costs and other development previously funded through government grants. Research and development expenses will be subject to quarterly variability due primarily to the number, size and timing of semiconductor fabrication runs and their associated cost as well as the timing and cost of other major development activities.
General and Administrative Expenses. General and administrative expenses increased by $131,119, or 22%, to $734,637 in the three months ended June 30, 2022 from $603,518 in the three months ended June 30, 2021. The increase was due to higher stock-based compensation expense of $45,974, professional fees of $27,581, Board fees and expenses of $20,554, personnel costs of $18,392 and other costs of $18,618. We expect flat to modestly lower general and administrative expenses in the remainder of 2022.
Sales and Marketing Expenses. Sales and marketing expenses increased by $121,119, or 108%, to $233,152 in the three months ended June 30, 2022 from $112,033 in the three months ended June 30, 2021. The increase was due to higher personnel costs of $44,578, as we hired our first two sales and marketing employees in 2021, professional fees of $22,633, stock-based compensation expense of $22,100, travel costs of $15,392 and other spending of $16,416. We expect higher sales and marketing expenses in the remainder of 2022 as we engage more broadly with prospective customers and continue the commercialization of our B-TRAN™ technology.
Loss from Operations. Our loss from operations for the three months ended June 30, 2022 was $1,696,172, or 33% higher, than the $1,276,244 loss from operations for the three months ended June 30, 2021 for the reasons discussed above.
Other Income. Other income was $6,178 for the three months ended June 30, 2022 compared to $89,551 for the three months ended June 30, 2021. The other income in the three months ended June 30, 2021 related primarily to a gain on forgiveness of long-term debt of $91,407.
Net Loss. Our net loss for the three months ended June 30, 2022 was $1,689,994, or 42% higher, as compared to a net loss of $1,186,693 for the three months ended June 30, 2021, for the reasons discussed above.
15
Comparison of the six months ended June 30, 2022 to the six months ended June 30, 2021
Grant Revenues. Grant revenues for the six months ended June 30, 2022 and 2021 were $175,986 and $326,766, respectively. The grant revenues relate primarily to a $1.2 million subcontract with DTI discussed above.
In September 2021, we entered into and began work under a $50,000 subcontract with DTI under a Phase I Small Business Innovation Research (“SBIR”) grant from the U.S. Department of Energy to develop a B-TRAN™-driven low loss alternating current SSCB. We completed our work under this subcontract in February 2022.
Cost of Grant Revenues. Cost of grant revenues for the six months ended June 30, 2022 and 2021 was $175,986 and $326,766, respectively. The cost of grant revenues relates to the subcontracts with DTI discussed above and are equal to the associated grant revenues resulting in no gross profit.
Research and Development Expenses. Research and development expenses increased by $735,357, or 90%, to $1,556,930 in the six months ended June 30, 2022 from $821,573 in the six months ended June 30, 2021. The increase was due to higher semiconductor fabrication costs of $365,598, stock-based compensation expense of $152,865, personnel costs of $110,903, wafer and driver component costs of $96,594 and other B-TRAN™ spending of $9,397. In the six months ended June 30, 2021, our semiconductor fabrication costs were partially funded by government grants. In the six months ended June 30, 2022, almost all of our semiconductor fabrication costs were not funded by government grants.
General and Administrative Expenses. General and administrative expenses increased by $383,382, or 32%, to $1,587,586 in the six months ended June 30, 2022 from $1,204,204 in the six months ended June 30, 2021. The increase was due to higher investor relations spending, inclusive of services paid in stock, of $109,770, stock-based compensation expense of $101,275, Board search and placement fees and expenses of $91,495, professional fees of $31,645, insurance of $23,448 and other costs of $25,749.
Sales and Marketing Expenses. Sales and marketing expenses increased by $277,970, or 159%, to $452,581 in the six months ended June 30, 2022 from $174,611 in the six months ended June 30, 2021. The increase was due to higher personnel costs of $138,534, as we hired our first two sales and marketing employees in 2021, stock-based compensation of $54,455, travel costs of $29,056, professional fees of $23,800 and other spending of $32,125.
Loss from Operations. Our loss from operations for the six months ended June 30, 2022 was $3,597,097, or 63% higher, than the $2,200,388 loss from operations for the six months ended June 30, 2021 for the reasons discussed above.
Other Income. Other income was $2,462 for the six months ended June 30, 2022 compared to $89,545 for the six months ended June 30, 2021. The other income in the six months ended June 30, 2021 related primarily to a gain on forgiveness of long-term debt of $91,407.
Net Loss. Our net loss for the six months ended June 30, 2022 was $3,594,635, or 70% higher, as compared to a net loss of $2,110,843 for the six months ended June 30, 2021, for the reasons discussed above.
Liquidity and Capital Resources
We currently generate grant revenue only. We expect to generate grant revenue and potentially commercial revenue in late 2022, depending on the ultimate date that our initial product is introduced for commercial sale and the timing of any development agreements that we may enter into with potential customers. We have incurred losses since inception. We have funded our operations to date through the sale of common stock and warrants.
At June 30, 2022, we had cash and cash equivalents of $20.0 million. Our net working capital at June 30, 2022 was $19.9 million. We had no outstanding debt at June 30, 2022. Accordingly, we expect that our cash and cash equivalents will be sufficient to fund our activities for at least the next twelve months from the date of filing this Quarterly Report on Form 10-Q; however, we may require additional funds to fully implement our plan of operation and business strategy.
16
Operating activities in the six months ended June 30, 2022 resulted in cash outflows of $3,081,517, which were due to the net loss for the period of $3,594,635 and unfavorable changes in net working capital of $138,271, partly offset by stock-based compensation of $462,238, stock issued for services of $100,100 and depreciation and amortization of $89,051. Operating activities in the six months ended June 30, 2021 resulted in cash outflows of $1,801,095, which were due primarily to the net loss for the period of $2,110,843 and a non-cash gain on loan forgiveness of $91,407, partly offset by stock-based compensation of $153,644, favorable balance sheet timing of $107,960, depreciation and amortization of $70,343 and stock issued for services of $68,680.
We expect an increase in cash outflows from operating activities throughout the remainder of 2022 as we continue to accelerate development and commercialization of our B-TRAN™ technology.
Investing activities in the six months ended June 30, 2022 and 2021 resulted in cash outflows of $67,920 and $145,019, respectively, for the acquisition of intangible assets and fixed assets. We expect an increase in cash outflows from investing activities during the second half of 2022 as we intend to acquire equipment to enhance our internal testing capabilities.
Financing activities in the six months ended June 30, 2022 did not result in any cash inflows or outflows. Financing activities in the six months ended June 30, 2021 resulted in cash inflows of $21,204,609 from the net proceeds from our Public Offering (as defined below) in February 2021 and $3,301,226 from the exercise of warrants and stock options.
Public Offering
In February 2021, we issued and sold 1,352,975 shares of our common stock, including 176,475 additional shares of common stock pursuant to the exercise of the underwriter’s option to purchase additional shares in full, in an underwritten public offering at a price of $17.00 per share (the “Public Offering”). The net proceeds to us from the Public Offering were $21.2 million. We are utilizing, and continue to expect to utilize, the net proceeds from the Public Offering to fund commercialization and development of our B-TRAN™ technology and general corporate and working capital purposes.
Critical Accounting Estimates
There have been no significant changes during the six months ended June 30, 2022 to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Trends, Events and Uncertainties
There are no material changes from trends, events or uncertainties disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, we are not required to provide this information.
17
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The Company’s disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company conducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act), under the supervision and with the participation of its Chief Executive Officer (principal executive officer) and its Chief Financial Officer (principal financial and accounting officer) of the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2022 and has concluded that, as of June 30, 2022, the Company’s disclosure controls and procedures are effective.
Changes in Internal Control over Financial Reporting
There have been no material changes in our internal controls over financial reporting that occurred during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
Limitations on the Effectiveness of Controls
Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any system of controls must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
18
PART II-OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We may be subject to litigation from time to time in the ordinary course of business. We are not currently party to any legal proceedings.
ITEM 1A. RISK FACTORS
There are no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
19
ITEM 6. EXHIBITS
Exhibit |
| Document |
31.1* | ||
31.2* | ||
32.1** | ||
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| ||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
10.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). |
* | Filed herewith |
**Furnished herewith
20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated August 15, 2022 | IDEAL POWER INC. | |
|
| |
| By: | /s/ R. Daniel Brdar |
|
| R. Daniel Brdar |
|
| Chief Executive Officer |
|
|
|
| By: | /s/ Timothy W. Burns |
|
| Timothy W. Burns |
|
| Chief Financial Officer |
21